WASHINGTON — The Drug Enforcement Administration has increased the production limit for the ADHD drug Vyvanse and its generic versions to combat the medicine's ongoing shortage, according to a notice posted this week.
The move comes after a request submitted by the U.S. Food and Drug Administration in July, the DEA said in its notice first reported by Bloomberg News.
The raised production limit comes out to about a 24% increase, according to Reuters.
ADHD drugs have been in short supply for multiple years. Back in Oct. 2022, the U.S. Food and Drug Administration officially announced a shortage of the ADHD treatment Adderall due to a manufacturing problem.
That led to a subsequent shortage of Takeda Pharmaceutical’s ADHD drug Vyvanse.
Vyvanse, also known as lisdexamfetamine, is classified as a schedule II controlled substance so it's subject to additional limits.
"These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine to meet legitimate patient needs both domestically and globally," the DEA said in its filing.
Last year, the FDA approved generic versions of Vyvanse from 11 drugmakers after Takeda lost exclusivity over the drug.